Aktuelles & Neues von uns und unseren Kunden
YM BIOSCIENCES REPORTS FISCAL THIRD QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
09. Mai 2008Thursday May 8, 8:56 pm ET
YM BIOSCIENCES ANNOUNCES SCHEDULE OF NIMOTUZUMAB PRESENTATIONS AT ASCO 2008 ANNUAL MEETING
06. Mai 2008Monday May 5, 5:21 pm ET
Ym Biosciences Announces Presentations for Aerolef(TM) at American Pain Society Annual Meeting
05. Mai 2008Monday May 5, 1:00 am ET
Ym Biosciences Announces Presentations for Two of its Anti-Cancer Drugs at Aacr Annual Meeting
11. April 2008MISSISSAUGA, ON, April 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX: YMI, TSX: YM, AIM: YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today...
YM BIOSCIENCES USA ENROLLS FIRST PATIENT IN PHASE II TRIAL OF NIMOTUZUMAB IN CHILDREN WITH INOPERABLE, RECURRENT BRAIN CANCER
13. Februar 2008Wednesday February 13, 7:00 am ET